Therapeutics News and Research

RSS

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Nektar Therapeutics announced today that data presented at the European Society for Medical Oncology (ESMO) 12th World Congress on Gastrointestinal Cancer demonstrates that NKTR-102, the company's lead oncology compound, exhibits superior activity compared to irinotecan as part of either a monotherapy or combination regimen in tumor models of gastrointestinal cancers.

7 Jul 2010

Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints

Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from its ongoing AZX100 Phase 2a clinical trial in trocar site scarring following arthroscopic shoulder surgery. Based on this analysis, the clinical trial will continue to its planned 12-month endpoints.

7 Jul 2010

Molecular Templates enters into oncology drug discovery and translation research agreement with ImClone

Molecular Templates announced today that it has entered into a collaborative oncology drug discovery and translation research agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company.

7 Jul 2010

Perseid Therapeutics achieves second milestone for CTLA4-Ig therapeutics

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a second preclinical milestone under its collaboration with Astellas Pharma Inc. to co-develop and commercialize next-generation CTLA4-Ig therapeutics.

7 Jul 2010

PhyloTech closes $1.2M Seed financing round

PhyloTech, Inc., announced today it closed a $1.2 M Seed financing round in June. The Company provides analysis of over 50,000 bacterial and archaeal taxa in samples from any source to solve problems in human health, environmental damages assessment, bioremediation, recreational water quality, drinking water and food safety, and an array of other applications.

7 Jul 2010

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

Angion Biomedica Corp., a biopharmaceutical company dedicated to the discovery and development of novel therapeutics that enhance quality of life, eradicate disease and save lives by modulating the body's protective, reparative and regenerative systems, announced today that its lead therapeutic BB3 was accepted into the Fast Track program of the U.S. Food and Drug Administration (FDA) and has also been designated an Orphan Drug product by FDA.

7 Jul 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

EUSA grants Ohara Japanese rights to Erwinase oncology therapy

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has granted the Japanese development and commercialization rights to its oncology therapy Erwinase(R) to Ohara Pharmaceutical Company Limited. The agreement represents the first product partnership EUSA has established in Japan.

6 Jul 2010

Hope for ovarian cancer patients not responding to conventional chemotherapy

Investigators at the Translational Genomics Research Institute (TGen) have discovered a way that may help ovarian cancer patients who no longer respond to conventional chemotherapy.

6 Jul 2010

$CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL$

CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL

Cell Therapeutics, Inc. announced today that it has submitted an expanded Pediatric Investigation Plan to the European Medicines Agency, as part of the process for its submission for a Marketing Authorization Application for pixantrone in the E.U. for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).

6 Jul 2010

Novel therapy slows tumor growth in 85% of advanced breast cancer patients: Study

A novel therapy designed to attack tumors in patients with a genetic mutation in either BRCA1 or BRCA2, slowed tumor growth in 85 percent of advanced breast cancer patients treated in a small study, researchers report in the July 6 issue of The Lancet.

6 Jul 2010

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Neogenix Oncology announced today that the company has filed a patent application with the U.S. Patent and Trade Office (USPTO) for the 16C3 antigen. The Company believes that this antigen is tumor specific for pancreatic and colorectal tumors; and, based on preliminary clinical data, may also have diagnostic utility as a biomarker for these cancers.

3 Jul 2010

Eli Lilly, Alnara sign definitive merger agreement

Eli Lilly and Company and Alnara Pharmaceuticals, Inc. today announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT).

2 Jul 2010

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.

2 Jul 2010

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Compugen Ltd. announced today that administration of CGEN-15001 in an animal model of multiple sclerosis (MS) has been shown to completely abolish spontaneous relapses. In addition, administration of this novel molecule prior to disease onset demonstrated a pronounced delay of disease onset and a significant decrease in disease symptoms.

2 Jul 2010

Biomimetic Therapeutics to discuss Augment Bone Graft data results at AOFAS meeting

BioMimetic Therapeutics, Inc. today announced its schedule of events at the American Orthopaedic Foot and Ankle Society (AOFAS) summer meeting being held at the Gaylord National Hotel and Convention Center in National Harbor, Maryland from July 7 - 10, 2010.

2 Jul 2010

China PharmaHub announces new joint venture for humanized antibody

China PharmaHub Corp., announced today that it has entered into a definitive agreement with Dr. David Weaver and Dr. Michael Rynkiewicz. In addition, PharmaHub contemplates merging with World Wide Relics, Inc. of which it recently purchased a 77% interest.

2 Jul 2010

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

United Therapeutics Corporation and Lee's Pharmaceutical Holdings Ltd. announced today that they have entered into an exclusive agreement for the distribution of Remodulin (treprostinil) Injection in China. Remodulin is a subcutaneously or intravenously administered prostacyclin analogue for the treatment of pulmonary arterial hypertension. Lee's Pharmaceutical is a leading Chinese pharmaceutical company with both a strong cardiovascular focus and extensive commercialization experience.

2 Jul 2010

Advanced Cancer Therapeutics secures $10M in investments

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.

2 Jul 2010

FIOCRUZ receives Brazil's Anvisa regulatory approval to market Chembio's Dual Path Platform HIV 1/2 rapid test

Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.

1 Jul 2010

Therapeutics News and Research

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Capstone Therapeutics to continue AZX100 Phase 2a trial in dermal scarring to planned 12-month endpoints

Molecular Templates enters into oncology drug discovery and translation research agreement with ImClone

Perseid Therapeutics achieves second milestone for CTLA4-Ig therapeutics

PhyloTech closes $1.2M Seed financing round

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

EUSA grants Ohara Japanese rights to Erwinase oncology therapy

Hope for ovarian cancer patients not responding to conventional chemotherapy

CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL

Novel therapy slows tumor growth in 85% of advanced breast cancer patients: Study

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Eli Lilly, Alnara sign definitive merger agreement

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Biomimetic Therapeutics to discuss Augment Bone Graft data results at AOFAS meeting

China PharmaHub announces new joint venture for humanized antibody

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

Advanced Cancer Therapeutics secures $10M in investments

FIOCRUZ receives Brazil's Anvisa regulatory approval to market Chembio's Dual Path Platform HIV 1/2 rapid test

Advancing therapeutic biopolymer development eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News